Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a clinical-stage biotech filing can feel like running a lab experiment without the protocol. Vor Biopharma’s 10-K spans pages of gene-editing details, cash-burn tables, and licensing clauses that leave many investors asking, “Where do I start?”
Stock Titan answers with AI-powered clarity. Our platform scans every new document the second it lands on EDGAR—whether it’s an 8-K material events notice on fresh trial data or a Form 4 insider transaction that hints at executive sentiment. Type a natural question like “understanding Vor Biopharma SEC documents with AI” or “how to read the Vor Biopharma annual report 10-K simplified,” and get plain-English summaries, key financial metrics, and direct page links within seconds.
Here’s what you can explore in one dashboard:
- Vor Biopharma quarterly earnings report 10-Q filing—AI highlights shifts in R&D spend and runway.
- Vor Biopharma insider trading Form 4 transactions—real-time alerts on buys, sells, and option grants.
- Vor Biopharma proxy statement executive compensation—breakdowns of equity awards tied to clinical milestones.
- Vor Biopharma 8-K material events explained—speed-read summaries of trial pauses, FDA designations, or financing rounds.
Need deeper context? Our AI cross-references historical filings for trendlines, delivering a concise Vor Biopharma earnings report filing analysis with year-over-year R&D and dilution impacts. Investors monitoring “Vor Biopharma Form 4 insider transactions real-time” or evaluating risk factors no longer have to sift through biotech jargon—Stock Titan surfaces what matters so you can focus on decisions, not documents.
Vor Biopharma reported a dramatic net loss of $1.606 billion for the six months ended June 30, 2025, driven primarily by a $1.299 billion non-cash increase in the fair value of newly issued warrant liabilities. The company held $200.6 million of cash, cash equivalents and marketable securities at June 30, 2025, and raised $174.4 million of net proceeds from a June 2025 private placement of PIPE warrants, which management says alleviated prior substantial doubt about near-term liquidity.
The company in-licensed telitacicept from RemeGen, paying a $45.0 million upfront cash fee and issuing RemeGen warrants initially valued at $177.4 million, and recorded a $222.6 million research and development charge as part of that acquisition. Vor also implemented a Restructuring Plan in May 2025, reducing headcount by 154 employees (about 99%) and recording $30.7 million of restructuring costs, leaving a remaining severance liability of $11.5 million at June 30, 2025. Total assets were $205.4 million and stockholders' deficit was $(1,505.7) million at period end.
Vor Biopharma Inc. (VOR) Form 144 disclosure shows a proposed sale of 18,382 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,407.39 and an approximate sale date of 08/11/2025 on NASDAQ. The filing records that these shares were acquired as restricted stock on 08/01/2025 (12,696 shares) and 08/06/2025 (5,686 shares).
The notice also lists multiple sales by Robert Ang in June–July 2025 totaling 1,134,988 shares with gross proceeds of about $2,544,405.10. Several issuer and filer identification fields (including issuer name and filer CIK) are left blank in the form.
Vor Biopharma’s August 25 2025 virtual special meeting asks holders to approve three material proposals:
- Issuance Proposal – authorize the full issuance of up to 1.02 billion common shares upon exercise of pre-funded and RemeGen warrants sold on 25 Jun 2025 for $175 million gross; warrants carry a $0.0001 exercise price and cannot be exercised until shareholder approval and an increase in authorized share count are effective.
- Reverse Stock Split – empower the Board to enact, any time within one year, a one-for-5 to one-for-30 split to lift the per-share price and expand unissued, unreserved shares, thereby preserving Nasdaq listing and providing headroom for the warrant shares and future corporate purposes.
- Equity Plan Amendment – add 25 million shares to the 2021 Equity Incentive Plan, reduce annual evergreen increases from 5 % to 4 % and extend the evergreen through 2035.
Support agreements covering ≈62.1 % of voting power commit to vote “FOR” all three items, virtually ensuring passage. Failure to approve the issuance would block warrant exercise and force repeat meetings every 90 days, consuming cash and delaying access to $175 million. Non-approval of the split could risk future Nasdaq bid-price compliance and limit share availability. Each proposal requires a simple majority of votes cast; broker non-votes and abstentions are not counted.
Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.
- Securities for sale: 29,432 common shares.
- Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
- Proposed sale date: 08 / 04 / 2025 on NASDAQ.
- Aggregate market value of planned sale: $61,589.40.
- Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
- Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.
No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR’s capital structure.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
